Impact of Serum Creatinine– and Cystatin C–Based Sarcopenia Index on Renal Outcomes in Non–Dialysis-Dependent Chronic Kidney Disease Patients: Results From the KNOW-CKD Study

Objective

To evaluate the impact of the serum creatinine– and cystatin C–based new sarcopenia index (SI) on renal outcomes in non–dialysis-dependent patients with chronic kidney disease (CKD).

Methods

In this observational Korean Cohort Study for Outcome in Patients With CKD (KNOW-CKD), 1957 patients with CKD stage 1 to stage 4 were analyzed from 2011 to 2019. Men and women were separately assigned to quartile groups according to their SI. The primary outcome was a composite renal outcome consisting of 50% reduction in estimated glomerular filtration rate or end-stage kidney disease. With use of Fine and Gray subdistribution hazard models, the association between the SI and the primary outcome was analyzed.

Results

During a median follow-up of 6.0 (4.2 to 7.7) years, the primary composite renal outcome occurred in 528 (28.6%) patients within a median of 3.0 (1.8 to 5.0) years. In unadjusted and adjusted models, lower SI groups had a poor primary outcome compared with the highest group (quartile 4). The hazard ratios for quartiles 1, 2, and 3 compared with quartile 4 in the fully adjusted model were 4.47 (95% CI, 3.05 to 6.56; P<.001), 3.08 (95% CI, 2.13 to 4.48; P<.001), and 2.09 (95% CI, 1.45 to 3.01; P<.001), respectively. Restricted cubic spline regression analyses found a relatively inverse linear relationship between the SI and the composite renal outcome.

Conclusion

The new SI is an independent predictor of renal outcomes. A low SI is associated with poor renal outcome.